Biochimica et biophysica acta. Reviews on cancer最新文献

Steroidal derivatives in pancreatic cancer: Paving the way to new anticancer drugs. 胰腺癌中的类固醇衍生物：为新的抗癌药物铺平道路。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-03 DOI: 10.1016/j.bbcan.2025.189468

Ana R Gomes, Elisiário J Tavares-da-Silva, Fernanda M F Roleira, Ana S Pires

{"title":"Steroidal derivatives in pancreatic cancer: Paving the way to new anticancer drugs.","authors":"Ana R Gomes, Elisiário J Tavares-da-Silva, Fernanda M F Roleira, Ana S Pires","doi":"10.1016/j.bbcan.2025.189468","DOIUrl":"10.1016/j.bbcan.2025.189468","url":null,"abstract":"Pancreatic cancer remains one of the most life-threatening cancers worldwide with limited therapeutic options and a poor prognosis. Despite the advances in treatment regimens, the death rate of pancreatic cancer patients continues to rise, justifying the need for novel therapeutic agents. Steroidal derivatives, with their unique modifiable framework, have emerged as a promising class of compounds in drug discovery, namely for the search for novel anticancer drugs. A comprehensive review of studies on the anticancer activity of synthetic and natural steroidal derivatives for potential pancreatic cancer treatment was conducted, highlighting their structural versatility, mechanisms of action, and recent advances in their development. For this, an extensive literature search was conducted in two main databases - PubMed and Web of Science. In the preclinical setting, the steroidal derivatives described throughout this review display their cytotoxicity by different mechanisms, which culminate in cell death mostly by apoptosis. Remarkably, many of the pathways affected by this class of compounds are considered key players in many of the hallmarks of cancer, which reinforces the importance of studying steroidal derivatives for the treatment of pancreatic cancer. This review summarises the current state of research and underscores the potential of steroidal derivatives as a groundwork for novel therapeutic approaches in pancreatic cancer management, outlining future directions for their development as effective anticancer agents.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189468"},"PeriodicalIF":8.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing oncology drug development: Innovative approaches to enhance success rates while reducing animal testing. 推进肿瘤药物开发：创新方法提高成功率，同时减少动物试验。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-02 DOI: 10.1016/j.bbcan.2025.189467

Hans Hendriks

{"title":"Advancing oncology drug development: Innovative approaches to enhance success rates while reducing animal testing.","authors":"Hans Hendriks","doi":"10.1016/j.bbcan.2025.189467","DOIUrl":"https://doi.org/10.1016/j.bbcan.2025.189467","url":null,"abstract":"Drug development remains a high-risk endeavour, particularly in oncology, where failure rates exceed 90 %. This review examines emerging tools and strategies designed to enhance preclinical success rates, aligning with the 3Rs principle: Reduction, Refinement, and Replacement of animal testing. Traditional 2D in vitro screening remains fundamental in early anticancer drug development due to its cost-effectiveness and reproducibility. However, 3D in vitro culture systems, including patient-derived organoids, better recapitulate tumour structure, providing more accurate predictions of clinical response. Additionally, Organ-on-a-chip platforms further enhance physiological relevance and complement conventional animal toxicology models. Despite their promise, these technologies face challenges in standardisation, validation, and regulatory acceptance. Artificial intelligence is also emerging as a transformative tool in oncology drug discovery and development. However, its widespread adoption is currently constrained by limited access to high-quality datasets, concerns around data security, privacy, and underdeveloped computational infrastructure. For in vivo studies, patient-derived xenograft (PDX) models remain the gold standard, offering robust and translationally relevant platforms for efficacy testing. Hybrid models, such as PDX-derived organoids and PDX-derived cell cultures, provide complementary systems that integrate in vitro and in vivo insights. While these innovations offer long-term potential to reduce animal use, more innovative experimental designs and methods, such as the Single Mouse Trial and the Hollow Fibre Assay, may reduce animal numbers in the short term without compromising data quality. Together, these advances contribute to a more ethical, efficient, and predictive framework for the development of preclinical anticancer drugs.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189467"},"PeriodicalIF":8.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to "Snail1 as a key prognostic biomarker of cancer-associated fibroblasts in breast tumors" [Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, volume 1880 (2025) / 189316]. “Snail1作为乳腺肿瘤中癌症相关成纤维细胞的关键预后生物标志物”的修正[biochemica et Biophysica Acta (BBA) - Reviews on Cancer, volume 1880(2025) / 189316]。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-02 DOI: 10.1016/j.bbcan.2025.189462

Raúl Peña, Josep Baulida

引用次数: 0

The role of tissue factor in the tumor microenvironment and targeted therapy. 组织因子在肿瘤微环境中的作用及靶向治疗。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1016/j.bbcan.2025.189409

Ying Yan, Yifan Li, Dan Zou, Huanhuan Ma, Hao Chen

引用次数: 0

Taurine and cancer: Biological properties and multifaceted roles in cancer progression. 牛磺酸与癌症：生物学特性和癌症进展中的多方面作用。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-07-29 DOI: 10.1016/j.bbcan.2025.189403

Rong Liu, Xinze Li, Zhenyu Hua, ZhiTong Liu, ZhengYue Wang, Xiang Li

引用次数: 0

The immunosuppressive microenvironment modulated by glioma-associated mesenchymal stem cells: Current status and potential strategies. 胶质瘤相关间充质干细胞调节的免疫抑制微环境：现状和潜在策略。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1016/j.bbcan.2025.189410

Yuyi Wu, Qiang Liu, Wei Xiang, Peng Fu

{"title":"The immunosuppressive microenvironment modulated by glioma-associated mesenchymal stem cells: Current status and potential strategies.","authors":"Yuyi Wu, Qiang Liu, Wei Xiang, Peng Fu","doi":"10.1016/j.bbcan.2025.189410","DOIUrl":"10.1016/j.bbcan.2025.189410","url":null,"abstract":"Glioma, the most prevalent primary malignant tumor of the central nervous system, exhibits aggressive progression and poor prognosis, largely due to its highly immunosuppressive tumor microenvironment (TME). Glioma-associated mesenchymal stem cells (GA-MSCs), a key component of the glioma TME, play a dual and context-dependent role in tumor biology. On one hand, GA-MSCs actively shape immunosuppression by interacting with various immune cells-including T cells, B cells, natural killer (NK) cells, dendritic cells (DCs), and macrophages-via soluble factors (e.g., TGF-β, PGE2, miR-21) and cell-contact mechanisms, thereby facilitating tumor immune evasion. They also promote glioma progression by enhancing the stemness, invasiveness, and chemoresistance of glioma stem cells (GSCs) through pathways such as IL-6/STAT3 and mitochondrial transfer, while contributing to pathological angiogenesis via differentiation into pericytes and secretion of pro-angiogenic factors like VEGF. On the other hand, GA-MSCs possess therapeutic potential: genetically engineered GA-MSCs can secrete pro-inflammatory cytokines (e.g., IL-12, IFN-β) or immune checkpoint blockers (e.g., scFv-PD1) to reverse immunosuppression, serve as carriers for targeted delivery of chemotherapeutics, miRNAs, suicide genes, or oncolytic viruses, and enhance anti-tumor immune responses. However, clinical translation is hindered by challenges including residual immunosuppressive activity, unstable transgene expression, limited migration efficiency, and safety concerns. This review summarizes the complex mechanisms by which GA-MSCs modulate the glioma TME, highlights their bidirectional roles in tumor progression and immunotherapy, and discusses potential strategies to overcome current limitations, aiming to provide insights for developing novel therapies targeting GA-MSCs and their interactions within the glioma microenvironment.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189410"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical aspect of combined immunotherapy and radiotherapy effect on tumor immune microenvironment in hepatobiliary and pancreatic cancers. 免疫放化疗联合治疗对肝胆胰肿瘤免疫微环境影响的临床研究。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-08-05 DOI: 10.1016/j.bbcan.2025.189406

Jun-Jie Cheng, Qiu-Yi Zheng, Yi-Lan Huang, Yi-Xing Chen, Shi-Suo Du

{"title":"Clinical aspect of combined immunotherapy and radiotherapy effect on tumor immune microenvironment in hepatobiliary and pancreatic cancers.","authors":"Jun-Jie Cheng, Qiu-Yi Zheng, Yi-Lan Huang, Yi-Xing Chen, Shi-Suo Du","doi":"10.1016/j.bbcan.2025.189406","DOIUrl":"10.1016/j.bbcan.2025.189406","url":null,"abstract":"Hepatobiliary and pancreatic cancers (HBPCs) remain among the most aggressive nature and lethal malignancies, presenting formidable challenges in their treatment. Surgical resection remains the cornerstone of curative treatment for early-stage HBPCs; however, advanced cases often necessitate a multidisciplinary systematic approach incorporating radiotherapy and immunotherapy. In recent years, innovations in radiotherapy technology have facilitated the precise and targeted delivery of tumoricidal doses, minimizing damage to surrounding normal tissue and expanding the application of radiotherapy in treating HBPCs. Moreover, the intricate impact of radiotherapy on the tumor immune microenvironment (TIME) is being increasingly understood. Synergizing radiotherapy with immunotherapy to induce a robust and sustained antitumor immune response, both locally at the irradiated site and systemically throughout the body, represents a promising and increasingly critical avenue of current research. This review begins by delineating the heterogeneity of the TIME in HBPCs and discusses how radiotherapy can either stimulate or suppress the TIME under various conditions. It also highlights recent preclinical and clinical advances in combining radiotherapy with immunotherapy, which have shown potential in improving local control rates and inducing systemic antitumor responses. This emerging paradigm warrants sustained research to fully realize its therapeutic potential in HBPC management.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189406"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decoding the key hallmarks of chemoresistance: A proteomic tale from breast cancer research. 解读化疗耐药的关键特征：乳腺癌研究中的蛋白质组学故事。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-07-30 DOI: 10.1016/j.bbcan.2025.189404

Praneeta Pradip Bhavsar, Bhargab Kalita, Khushman Taunk, Srikanth Rapole

{"title":"Decoding the key hallmarks of chemoresistance: A proteomic tale from breast cancer research.","authors":"Praneeta Pradip Bhavsar, Bhargab Kalita, Khushman Taunk, Srikanth Rapole","doi":"10.1016/j.bbcan.2025.189404","DOIUrl":"10.1016/j.bbcan.2025.189404","url":null,"abstract":"Chemoresistance denotes the intricate, multifactorial molecular mechanisms by which malignant cells subvert the cytotoxicity of chemotherapeutic agents, thereby impeding therapeutic efficacy. This phenomenon is orchestrated through a confluence of processes, which we propose as the major hallmarks of chemoresistance in cancer. Dysregulation of drug transporters, activation of pro-survival pathways, cancer stem cell driven proliferation, DNA damage and repair mechanisms, evasion of apoptosis, autophagy induction, secretion of extracellular vesicles, and metabolic reprogramming represents the major mechanisms of chemoresistance in cancer. Breast cancer is one of the most common and aggressive types of cancer, with significant challenges in treatment due to its heterogeneity. Despite progress in various treatment regimens, chemoresistance continues to be a significant challenge in the effective management of breast cancer. In this context, high-throughput proteomic methodologies, which quantitatively assess proteome-wide alterations and explore post-translational modifications, can provide an unbiased framework for unraveling the molecular intricacies of chemotherapy resistance. This article comprehensively reviews the application of advanced proteomic techniques in elucidating the pathophysiological mechanisms of chemoresistance in breast carcer. Additionally, it highlights promising protein signatures uncovered via proteomic tools, as well as therapeutic strategies targeting chemoresistant hallmarks to overcome drug resistance in breast cancer. By leveraging the mightiness of proteomic technologies, we move closer to efficient, potent and personalized therapeutic interventions for chemoresistant breast cancer.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189404"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives. 结直肠癌肝转移中的异常与NETosis：关系及展望。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-07-29 DOI: 10.1016/j.bbcan.2025.189401

Ruoyu Zhang, Yunfei Tan, Dedi Jiang, Dewei Kong, Mei Liu, Jianwei Liang, Aiwen Wu, Liming Wang

{"title":"Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives.","authors":"Ruoyu Zhang, Yunfei Tan, Dedi Jiang, Dewei Kong, Mei Liu, Jianwei Liang, Aiwen Wu, Liming Wang","doi":"10.1016/j.bbcan.2025.189401","DOIUrl":"10.1016/j.bbcan.2025.189401","url":null,"abstract":"Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with metastatic spread being the primary reason for fatalities. Anoikis, a form of programmed cell death triggered by cell detachment from the extracellular matrix (ECM), and NETosis, a neutrophil cell death mode releasing extracellular traps (NETs), play critical roles in CRC liver metastasis (CRCLM). This review explores the mechanisms of anoikis and NETosis, their interplay, and genetic underpinnings in CRCLM. Anoikis resistance in CRC cells allows survival during metastasis in the initial stage, while NETs promote tumor progression by facilitating immune evasion, ECM remodeling, and angiogenesis. Meanwhile, through bioinformatics analysis and summary, we elaborated on the relationship between anoikis and NETosis as well as the potential interaction mechanisms, exploring the connecting links between them. The crosstalk between these processes is analyzed, highlighting shared signaling pathways (e.g., PI3K/AKT, MAPK, EMT) and potential biomarkers (e.g., MUC13, GLI2, SIRT6, FASN). Therapeutic strategies targeting anoikis and NETosis, including inhibitors of integrins, EGFR, and NET components (e.g., DNase I, CXCR2 antagonists), inhibitors of autophagy (e.g., CQ, HCQ, azithromycin) are discussed. This comprehensive analysis advances understanding of CRCLM pathogenesis and provides novel perspectives for targeted interventions.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189401"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reprogramming of amino acid metabolism in breast cancer. 乳腺癌中氨基酸代谢的重编程。

IF 8.3

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1016/j.bbcan.2025.189412

Meijin Wang, Yunlu Zhang, Zhenhua Li, Li Fu

{"title":"Reprogramming of amino acid metabolism in breast cancer.","authors":"Meijin Wang, Yunlu Zhang, Zhenhua Li, Li Fu","doi":"10.1016/j.bbcan.2025.189412","DOIUrl":"10.1016/j.bbcan.2025.189412","url":null,"abstract":"Breast cancer is one of the most prevalent malignant tumours, representing a significant health risk for women. Subtyping of breast cancer is based on gene expression profiles, with five distinct subtypes identified Luminal A, Luminal B, HER2-positive, basal-like and normal-like. The heterogeneity of breast cancer represents a significant challenge to its treatment, while drug resistance limits the effectiveness of existing therapies. There is widespread amino acid metabolic reprogramming in breast cancer, and the altered amino acid metabolism observed in breast cancer cells exhibits a heterogeneous metabolic phenotype that differs from normal cells. Consequently, targeting the metabolic differences between breast and normal cells may represent a promising novel anti-cancer strategy. In this article, we review the alterations in the metabolism of amino acids such as glutamine, cystine, serine, glycine, tryptophan and arginine in breast cancer and explore the specific mechanisms by which the aberrant expression of various amino acid metabolism-related enzymes leads to alterations in the proliferative, invasive and metastatic capacities of cancer cells. Finally, we summarise the drugs targeting amino acid metabolism in breast cancer that are currently in preclinical and clinical trials, providing a theoretical basis for targeted therapy of amino acid metabolism.","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189412"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0